GLP-1 Weight Loss Drugs (Ozempic, Wegovy, Mounjaro): Benefits, Risks, Muscle Loss, and the “Leverage” Mindset

Connect with Us:

Join our Investment Community over over 14,000: https://thewealthelevator.com/club

For Holistic Wellness and Performance Coaching: connect with Dr. Po at drpowu.com

The hosts discuss GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro—originally diabetes drugs that mimic a natural gut hormone to increase satiety, slow gastric emptying, reduce appetite signaling via the brain, and improve glucose control—now widely used for weight loss. They cite trials showing roughly 15–20% body-weight loss over about 68–72 weeks and note cardiovascular risk reductions in high-risk groups. Key downsides include loss of muscle mass if protein and resistance training aren’t prioritized, common GI side effects, rare serious risks like pancreatitis or gallbladder issues, uncertain long-term outcomes (including rodent thyroid findings not yet seen in humans), cost/insurance hurdles, and weight regain after stopping—raising whether it’s a bridge or chronic therapy. They also cover identity and “cognitive bandwidth” benefits from reduced food chatter, and close with practical takeaways: clarify goals, train and eat intentionally, plan maintenance, and adopt a healthy narrative about using tools as leverage.

00:00 GLP-1 Hype Begins

01:26 What GLP-1 Actually Is

03:31 Food Addiction Angle

04:26 Results From Trials

06:08 Downsides Muscle Loss

07:11 Shortcut Debate Ethics

10:53 Cost Access Insurance

11:25 Side Effects Regain Risks